• about us
• allosteric modulation
• pipeline
  • discovery pipeline
• key indications
• business development
• investor center
• press releases
• careers
• contact

GLP1R PAM

This series of glucagon like peptide-1 receptor (GLP1R) positive allosteric modulators (PAM) is in lead optimization for type II diabetes. A GLP1R PAM from this series could become the first orally available small molecule therapeutic agent against this target.

Back to discovery pipeline